AVTX vs. NNVC, TNXP, MIRA, TRAW, RDHL, ABVC, IMNN, EDSA, PPBT, and AGE
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include NanoViricides (NNVC), Tonix Pharmaceuticals (TNXP), MIRA Pharmaceuticals (MIRA), Traws Pharma (TRAW), RedHill Biopharma (RDHL), ABVC BioPharma (ABVC), Imunon (IMNN), Edesa Biotech (EDSA), Purple Biotech (PPBT), and AgeX Therapeutics (AGE). These companies are all part of the "pharmaceutical preparations" industry.
Avalo Therapeutics (NASDAQ:AVTX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations.
NanoViricides has lower revenue, but higher earnings than Avalo Therapeutics. NanoViricides is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avalo Therapeutics and Avalo Therapeutics both had 1 articles in the media. Avalo Therapeutics' average media sentiment score of 0.00 equaled NanoViricides'average media sentiment score.
Avalo Therapeutics received 5 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 31.25% of users gave Avalo Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 0.2% of Avalo Therapeutics shares are held by insiders. Comparatively, 4.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
NanoViricides has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -1,639.50%. NanoViricides' return on equity of -63.97% beat Avalo Therapeutics' return on equity.
Avalo Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Summary
Avalo Therapeutics beats NanoViricides on 7 of the 13 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
